Home > Insider Trading > Filing (0000905718-21-001373)

Filing Details

Accession Number:: 0000905718-21-001373
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2021-10-19 17:13:59
Reporting Period:: 2021-10-15

Accepted Time:: 2021-10-19 17:13:59
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1692830	Satsuma Pharmaceuticals Inc.	STSA	Pharmaceutical Preparations (2834)	813039831

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1831942	Commodore Capital Lp	767 Fifth Ave 12Th Floor New York NY 10153		No	No	Yes	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock, Par Value $0.0001 Per Share	Acquisiton	2021-10-15	126,000	$4.83	3,334,761	No	4	P	Indirect	By Commodore Capital Master LP
Common Stock, Par Value $0.0001 Per Share	Acquisiton	2021-10-18	36,194	$4.87	3,370,955	No	4	P	Indirect	By Commodore Capital Master LP

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	P	Indirect	By Commodore Capital Master LP
No	4	P	Indirect	By Commodore Capital Master LP

Footnotes

The shares are held directly by Commodore Capital Master LP ("Commodore Master"). Commodore Capital LP ("Commodore Capital") is the investment manager to Commodore Master. Michael Kramarz and Robert Egen Atkinson are the managing partners of Commodore Capital and exercise investment and dispositive power over the securities held by Commodore Master. Each of Commodore Capital, Mr. Kramarz and Mr. Atkinson disclaim beneficial ownership of such securities, except to the extent of their pecuniary interest therein. This report shall not be deemed an admission that Commodore Capital, Commodore Master, Mr. Kramarz and Mr. Atkinson or any other person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.
The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.75 to $4.90 per share, inclusive. The Reporting Person undertakes to provide to Issuer any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein.
The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.84 to $4.98 per share, inclusive. The Reporting Person undertakes to provide to Issuer any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein.